Abstract:OBJECTIVE:To study the expression levels of ANXA1 and ANXA2 and elucidate their clinicopathological significance in adenocarcinoma, peritumoral tissues, adenomatous polyp and chronic cholecystitis of gallbladder. METHODS:EnVision(TM) immunohistochemical staining was used to detect the expression of ANXA1 and ANXA2 in paraffin-embedded tissue sections from resected specimens of adenocarcinoma (n = 108), peritumoral tissue (n = 46), adenomatous polyp (n = 15) and chronic cholecystitis (n = 35). RESULTS:The positive rates and scores of ANXA1 and ANXA2 were significantly higher in adenocarcinoma (59.3%, 56.5%; 3.2 ± 0.9, 3.4 ± 0.8) than those in peritumoral tissues (34.8%, 1.1 ± 0.8, P < 0.01; 30.4%, 1.0 ± 0.8, P < 0.01), adenomatous polyp (26.7%, 0.9 ± 0.7, P < 0.05 or P < 0.01; 26.7%, 0.9 ± 0.8, P < 0.05 or P < 0.01) and chronic cholecystitis (17.1%, 0.7 ± 0.9, P < 0.01; 20.0%, 0.8 ± 0.8, P < 0.01). The benign lesions with positive ANXA1 and/or ANXA2 expression showed mild to severe atypical hyperplasia of the gallbladder epithelium. The positive rates of ANXA1 and/or ANXA2 were significantly lower in the well-differentiated adenocarcinoma, in a maximal diameter of < 2 cm, with no metastasis to lymph nodes and no invasion to surrounding tissues than those in the moderately or poorly-differentiated adenocarcinoma, in a maximal diameter of ≥ 2 cm, with metastasis to lymph nodes and invasion in surrounding tissues (P < 0.05 or P < 0.01). A high consistence was found between the expression levels of ANXA1 and ANXA2 (χ(2) = 67.84, P < 0.01), and a close positive correlation between the scores of ANXA1 and ANXA2 (r = 0.78, P < 0.01) in gallbladder adenocarcinoma. Kaplan-Meier analysis and multivariate Cox regression analysis showed that ANXA1 or ANXA2 was not an independent prognostic predictor in gallbladder adenocarcinoma. CONCLUSION:The expression levels of ANXA1 and/or ANXA2 may be important biological markers in the carcinogenesis, progression and biological behaviors of gallbladder adenocarcinoma.

Annexin A2 in Tumors of the Gastrointestinal Tract, Liver, and Pancreas

Association of annexin A2 with cancer development (Review).

Expression and Significance of Annexin A2 in Patients with Gastric Adenocarcinoma and the Association with E-cadherin.

Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers

Annexin I and Tumor

The Association of Annexin A2 with Malignant Tumor

Prognostic and Diagnostic Significance of Annexin A2 in Colorectal Cancer.

Advances in cancer treatment: a new therapeutic target, Annexin A2

Annexin A protein family: Focusing on the occurrence, progression and treatment of cancer.

Annexin A2 in Inflammation and Host Defense

[Expression of annexin A1 (ANXA1) and A2 (ANXA2) and its significance in benign and malignant lesions of gallbladder].

Differential Expression of ANXA1 in Benign Human Gastrointestinal Tissues and Cancers

Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis

Annexin A1 in Malignant Tumors: Current Opinions and Controversies.

Study Progress of AnnexinⅡ and Tumor

Annexin A2 is Implicated in Multi-Drug-resistance in Gastric Cancer Through P38mapk and AKT Pathway.

An overview of the regulatory role of annexin A1 in the tumor microenvironment and its prospective clinical application (Review)

Clinical significance of Annexin A2 expression in oral squamous cell carcinoma and its influence on cell proliferation, migration and invasion

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements

Annexin A4 and cancer

Annexin A1 in inflammation and breast cancer: a new axis in the tumor microenvironment